Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis
Objective – to compare the clinical efficacy and cost-effectiveness of IL-17 inhibitors (SEC, IXE, NTK) in the treatment of adult patients with ankylosing spondylitis (AS) in the healthcare system of the Russian Federation.Material and methods. The study is a sub-analysis of a previously published s...
Saved in:
Main Authors: | T. V. Dubinina, I. Z. Gaydukova, N. А. Sableva, K. V. Sapozhnikov, V. D. Sokolova, D. G. Tolkacheva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2022-12-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3249 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01) -
Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy
by: A. A. Godzenko, et al.
Published: (2023-10-01) -
Efficacy and safety of biologics for the treatment of ankylosing spondylitis: systematic literature review and network meta-analysis of treatments registered in the Russian Federation
by: T. V. Dubinina, et al.
Published: (2021-01-01) -
Clinical picture of ankylosing spondylitis in HLA-B27 positive and negative patients
by: Sh. F. Erdes, et al.
Published: (2023-10-01) -
Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial
by: Sh. Erdes, et al.
Published: (2019-12-01)